

**A) Amendments to the specification:**

1) Applicants respectfully request that the title be amended as follows:

**3-OXIMINO INDOLES AS INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)**

2) Applicants respectfully request that the following paragraph be added on page 1 after the title but before the TECHNICAL FIELD OF INVENTION:


**PRIORITY INFORMATION**

This application is a continuation application and claims benefit under 35 U.S.C. § 120 to co-pending PCT International Application PCT/US00/10866 filed April 21, 2000, and claims priority under 35 U.S.C § 119(e) to US Provisional Application serial number 60/130,752 filed April 23, 1999 and the entire contents of each of these applications are hereby incorporated by reference.

3) Applicants respectfully request that the abstract be amended as follows:

**ABSTRACT**

The present invention relates to 3-oximino indoles of formula I



useful as inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders or diseases including but not limited to inflammatory diseases, autoimmune

diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with proinflammatory cytokines.